Regeneratio Pharma

Regeneratio Pharma is a German biotechnology company primarily recognized for developing Regividerm, a specialized topical cream formulated with Vitamin B12 (cyanocobalamin) and avocado oil for the treatment of atopic dermatitis and psoriasis. The company rose to international prominence in 2009 following a high-profile German television documentary that alleged major pharmaceutical companies had suppressed the product's market entry to protect more expensive drug alternatives. Although the company faced significant corporate instability, including the bankruptcy of its original AG structure, it successfully licensed the commercial rights for its flagship treatment to the Swiss firm Mavena Health Care. Regeneratio Pharma's core scientific approach focuses on the use of cobalamins as scavengers of nitric oxide to reduce inflammatory symptoms in chronic skin conditions. The product remains available in various European markets under the Mavena B12 or Regeneratio B12 branding.